Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2020-003958-67-FR
EUCTR2020-003958-67-FR
Active, not recruiting
Phase 1

Phase II/III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging for the detection of PSMA positive tumors using histopathology as a standard of truth (GuideView) - GuideView

ovartis Pharma AG0 sites195 target enrollmentMarch 17, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsntreated high risk prostate cancerMedDRA version: 21.0Level: PTClassification code 10036918Term: Prostate cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ntreated high risk prostate cancer
Sponsor
ovartis Pharma AG
Enrollment
195
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 17, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Untreated high risk biopsy\-proven PCa patients according to D’Amico classification (Stage T2c or PSA level \>20ng/ml or Gleason score \=8\)
  • •2\. Scheduled or planned radical prostatectomy and extended pelvic lymph node resection up to 6 weeks after the investigational PET/CT scan followed by histopathology assessment
  • •3\. ECOG performance status 0\-2
  • •4\. Signed informed consent must be obtained prior to participation in the study
  • •5\. Participants must be adults \= 18 years of age
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 58
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •1\. Inability to complete the needed investigational and standard\-of\-care imaging examinations due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)
  • •2\. Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation, including, but not limited to, current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and COVID\-19\.
  • •3\. Known allergy, hypersensitivity, or intolerance to \[18F]CTT1057
  • •4\. Prior and current use of PSMA targeted therapies
  • •5\. Prior and current treatment with LHRH analogues
  • •6\. Any prior ADT (first or second generation) within 9 months before screening
  • •7\. Any 5\-alpha reductase inhibitors within 30 days before screening
  • •8\. Patients with small cell or neuroendocrine PCa in more than 50% of biopsy tissue
  • •9\. Patients with incidental PCa after transuretheral resection
  • •10\. Use of other investigational drugs within 30 days before screening

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Diagnostic performance of [18F]CTT1057 PET versus pathology
EUCTR2020-003958-67-ITOVARTIS PHARMA AG195
Active, not recruiting
Phase 1
Diagnostic performance of [18F]CTT1057 PET versus pathologyntreated high risk prostate cancerMedDRA version: 21.0Level: PTClassification code 10036918Term: Prostate cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-003958-67-ESovartis Farmacéutica, S.A.195
Not yet recruiting
Phase 2
Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide ReceptorCancerMalignancies known to overexpress GRPR10027655
NL-OMON46627Advanced Accelerator Applications International S.A.10
Active, not recruiting
Phase 1
Study of [68Ga]-NeoBOMB1 imaging in patients with malignancies known to overexpress GRPRMalignancies known to overexpress Gastrin-Releasing Peptide ReceptorsMedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-003432-37-ATAdvanced Accelerator Applications International SA50
Active, not recruiting
Phase 1
Diagnostic performance of [18F]CTT1057 PET in BCRProstate cancer with rising PSA levels [biochemical recurrence (BCR)]MedDRA version: 21.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-003959-16-ESovartis Farmacéutica S.A.190